The first one, which concerns the course of disease, is that lactate, invariably present in the low‐oxygen microenvironment of SCNs of BM, promotes the selection and maintenance of BCR/Abl‐independent CML stem/progenitor cell potential, which is a crucial factor to determine CML resistance to TKI therapy. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.